Trials / Completed
CompletedNCT02910557
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 187 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Conditions
Timeline
- Start date
- 2017-08-10
- Primary completion
- 2026-01-30
- Completion
- 2026-01-30
- First posted
- 2016-09-22
- Last updated
- 2026-02-05
Locations
23 sites across 5 countries: United States, Austria, Israel, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02910557. Inclusion in this directory is not an endorsement.